S&P 500   4,580.35 (+0.12%)
DOW   35,666.37 (-0.25%)
QQQ   382.64 (+0.93%)
AAPL   149.63 (+0.21%)
MSFT   325.42 (+4.94%)
FB   315.64 (-0.05%)
GOOGL   2,960.00 (+6.24%)
TSLA   1,044.77 (+2.59%)
AMZN   3,426.67 (+1.50%)
NVDA   248.40 (+0.50%)
BABA   169.20 (-0.46%)
NIO   39.80 (-1.66%)
CGC   12.94 (-1.75%)
GE   104.37 (-2.86%)
AMD   124.40 (+1.20%)
MU   68.19 (-1.09%)
T   25.15 (-0.87%)
F   15.69 (-1.57%)
ACB   6.89 (-1.99%)
DIS   170.16 (-1.09%)
PFE   42.88 (-1.56%)
BA   208.44 (-0.65%)
AMC   35.10 (-2.64%)
S&P 500   4,580.35 (+0.12%)
DOW   35,666.37 (-0.25%)
QQQ   382.64 (+0.93%)
AAPL   149.63 (+0.21%)
MSFT   325.42 (+4.94%)
FB   315.64 (-0.05%)
GOOGL   2,960.00 (+6.24%)
TSLA   1,044.77 (+2.59%)
AMZN   3,426.67 (+1.50%)
NVDA   248.40 (+0.50%)
BABA   169.20 (-0.46%)
NIO   39.80 (-1.66%)
CGC   12.94 (-1.75%)
GE   104.37 (-2.86%)
AMD   124.40 (+1.20%)
MU   68.19 (-1.09%)
T   25.15 (-0.87%)
F   15.69 (-1.57%)
ACB   6.89 (-1.99%)
DIS   170.16 (-1.09%)
PFE   42.88 (-1.56%)
BA   208.44 (-0.65%)
AMC   35.10 (-2.64%)
S&P 500   4,580.35 (+0.12%)
DOW   35,666.37 (-0.25%)
QQQ   382.64 (+0.93%)
AAPL   149.63 (+0.21%)
MSFT   325.42 (+4.94%)
FB   315.64 (-0.05%)
GOOGL   2,960.00 (+6.24%)
TSLA   1,044.77 (+2.59%)
AMZN   3,426.67 (+1.50%)
NVDA   248.40 (+0.50%)
BABA   169.20 (-0.46%)
NIO   39.80 (-1.66%)
CGC   12.94 (-1.75%)
GE   104.37 (-2.86%)
AMD   124.40 (+1.20%)
MU   68.19 (-1.09%)
T   25.15 (-0.87%)
F   15.69 (-1.57%)
ACB   6.89 (-1.99%)
DIS   170.16 (-1.09%)
PFE   42.88 (-1.56%)
BA   208.44 (-0.65%)
AMC   35.10 (-2.64%)
S&P 500   4,580.35 (+0.12%)
DOW   35,666.37 (-0.25%)
QQQ   382.64 (+0.93%)
AAPL   149.63 (+0.21%)
MSFT   325.42 (+4.94%)
FB   315.64 (-0.05%)
GOOGL   2,960.00 (+6.24%)
TSLA   1,044.77 (+2.59%)
AMZN   3,426.67 (+1.50%)
NVDA   248.40 (+0.50%)
BABA   169.20 (-0.46%)
NIO   39.80 (-1.66%)
CGC   12.94 (-1.75%)
GE   104.37 (-2.86%)
AMD   124.40 (+1.20%)
MU   68.19 (-1.09%)
T   25.15 (-0.87%)
F   15.69 (-1.57%)
ACB   6.89 (-1.99%)
DIS   170.16 (-1.09%)
PFE   42.88 (-1.56%)
BA   208.44 (-0.65%)
AMC   35.10 (-2.64%)
NASDAQ:GNOM

Global X Genomics & Biotechnology ETF Stock Forecast, Price & News

$21.42
-0.22 (-1.02 %)
(As of 10/27/2021 12:59 PM ET)
Add
Today's Range
$21.40
▼
$21.60
50-Day Range
$21.03
▼
$25.03
52-Week Range
$17.80
▼
$28.45
Volume182 shs
Average Volume119,901 shs
Market Capitalization$269.25 million
P/E RatioN/A
Dividend Yield0.15%
BetaN/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive GNOM News and Ratings via Email

Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.


Global X Genomics & Biotechnology ETF logo

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Headlines

Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Declines By 55.7%
October 14, 2021 |  americanbankingnews.com
Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Grows By 56.5%
October 4, 2021 |  americanbankingnews.com
Snag Next-Generation Tech Exposure with This Genomics ETF
July 16, 2021 |  nasdaq.com
ETF Battles: ARKG vs. GNOM - Which Is The Better Genomics/Biotech Play?
June 4, 2021 |  msn.com
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
December 29, 2020 |  msn.com
4 Best Sector ETFs of Q4
December 24, 2020 |  msn.com
Get On Board a Growing Biotech Industry With the GNOM ETF
December 23, 2020 |  nasdaq.com
Global X Genomics & Biotechnology ETF
November 26, 2020 |  barrons.com
ETF Wrap: A very ETF Thanksgiving, and tax season too
November 25, 2020 |  finance.yahoo.com
Global X Genomics & Biotechnology ETF (GNOM)
October 18, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
N/A
Sub-Industry
N/A
Sector
N/A
Current Symbol
NASDAQ:GNOM
Previous Symbol
CUSIP
N/A
CIK
1361103
Web
www.completegenomics.com
Phone
+1-650-9432800
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
12,570,000
Market Cap
$269.25 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Frequently Asked Questions

What stocks does MarketBeat like better than Global X Genomics & Biotechnology ETF?

Wall Street analysts have given Global X Genomics & Biotechnology ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Global X Genomics & Biotechnology ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 64,700 shares, a decline of 55.7% from the September 15th total of 146,200 shares. Based on an average daily trading volume, of 84,700 shares, the days-to-cover ratio is currently 0.8 days.
View Global X Genomics & Biotechnology ETF's Short Interest.

How has Global X Genomics & Biotechnology ETF's stock been impacted by Coronavirus (COVID-19)?

Global X Genomics & Biotechnology ETF's stock was trading at $12.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNOM shares have increased by 65.3% and is now trading at $21.42.
View which stocks have been most impacted by COVID-19.

How often does Global X Genomics & Biotechnology ETF pay dividends? What is the dividend yield for Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF declared a Semi-Annual dividend on Tuesday, December 29th. Shareholders of record on Thursday, December 31st will be paid a dividend of $0.032 per share on Friday, January 8th. The ex-dividend date is Wednesday, December 30th.
View Global X Genomics & Biotechnology ETF's dividend history.

Is Global X Genomics & Biotechnology ETF a good dividend stock?

Global X Genomics & Biotechnology ETF pays an annual dividend of $0.03 per share and currently has a dividend yield of 0.15%.
View Global X Genomics & Biotechnology ETF's dividend history.

What other stocks do shareholders of Global X Genomics & Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global X Genomics & Biotechnology ETF investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), (SNY), Intel (INTC), Pfizer (PFE), Quest Diagnostics (DGX), Micron Technology (MU), Dynavax Technologies (DVAX), (MRNA) and Matinas BioPharma (MTNB).

What is Global X Genomics & Biotechnology ETF's stock symbol?

Global X Genomics & Biotechnology ETF trades on the NASDAQ under the ticker symbol "GNOM."

Who are Global X Genomics & Biotechnology ETF's major shareholders?

Global X Genomics & Biotechnology ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Private Advisor Group LLC (4.30%), McGuire Investment Group LLC (2.76%), Creative Financial Designs Inc. ADV (0.14%) and IFP Advisors Inc (0.03%).

Which major investors are buying Global X Genomics & Biotechnology ETF stock?

GNOM stock was purchased by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, McGuire Investment Group LLC, Creative Financial Designs Inc. ADV, and IFP Advisors Inc.

How do I buy shares of Global X Genomics & Biotechnology ETF?

Shares of GNOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global X Genomics & Biotechnology ETF's stock price today?

One share of GNOM stock can currently be purchased for approximately $21.42.

How much money does Global X Genomics & Biotechnology ETF make?

Global X Genomics & Biotechnology ETF has a market capitalization of $269.25 million.

What is Global X Genomics & Biotechnology ETF's official website?

The official website for Global X Genomics & Biotechnology ETF is www.completegenomics.com.

Where are Global X Genomics & Biotechnology ETF's headquarters?

Global X Genomics & Biotechnology ETF is headquartered at 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States.

How can I contact Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF's mailing address is 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The company can be reached via phone at +1-650-9432800.


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.